#China #Qingdao #Global Sales #Laboratory Equipment #Haier Biomedical

Haier Biomedical Achieves Double No. 1 Ranking in Global Lab Equipment Sales

Haier Biomedical, a prominent name in life science laboratory equipment, has made waves in the industry by securing the top spot in global sales for laboratory equipment in biological sciences. According to the latest report from Euromonitor International for 2025, Haier not only claimed the title of the number one Chinese brand in this sector, but it also took first place in international sales, showcasing its impressive growth and market penetration.

This remarkable accomplishment positions Haier Biomedical as a leader in the fiercely competitive global market for laboratory equipment. The company's achievements are particularly noteworthy as they come on the heels of a strategic three-phase international expansion that has allowed Haier to consistently achieve a compound annual growth rate exceeding 20%.

The rankings released by Euromonitor International, a leading independent market research firm, are widely regarded as essential benchmarks for global procurement and industry analysis. The recognition indicates Haier's exceptional performance, not only in revenue but also in establishing a reputation for reliability in device functioning and compliance with regulatory standards.

This accolade holds significant implications for Haier's international partners. In an industry where purchasing decisions hinge on factors like equipment reliability, regulatory compliance, and long-term service support, having independent validation of market leadership adds a layer of assurance for institutions selecting suppliers.

Haier Biomedical's international growth has primarily stemmed from targeted initiatives in collaboration with organizations such as UNICEF and WHO, aimed at addressing unmet needs within communities. Notably, the company has established itself as a leader in solar-powered vaccine storage systems, further enhancing its role in global health efforts.

As part of its expansion strategy, Haier has broadened its distribution network to cover 160 countries, establishing over 800 active business relationships. Presently, the company focuses on building comprehensive operational capabilities in key regions, reinforcing its local warehouses, sales, marketing, product planning, and research and development efforts.

To this end, Haier operates foreign research and development centers in the UK, Italy, and Japan, each dedicated to specific product lines, including centrifuges, cold chain solutions, automated storage, incubators, and safety boxes. In the UK and continental Europe, specialized product experts provide on-site support regarding GMP compliance, air safety, and sample cleaning, positioning Haier Biomedical as a vital partner in laboratory operations.

Service standards established in the U.S. and the UK are being rolled out across the EU, Southeast Asia, and South Asia, ensuring uniform quality in service delivery. As of the first quarter of 2026, revenue growth has surpassed 50% in Germany, Australia, and Canada, while the annual growth rate in Eastern Europe, South Asia, and Brazil has exceeded 100%, with sales volumes of centrifuges and incubators doubling.

In the pharmaceutical sector, Haier Biomedical is integrated into the supply chains of leading pharmaceutical companies in key regions, including Switzerland, Germany, Denmark, Italy, Singapore, the U.S., Israel, and India. Moreover, its Ultra Energy series occupies all eight top spots in the Energy Star rankings within its category in the U.S., establishing it as the best-selling series in that segment.

Looking ahead, Haier Biomedical aims to further enhance localized investments and expand its product portfolio to assist global biopharmaceutical and life science laboratories in improving efficiency and sustainability. The company aspires to become a world leader in integrated tools for biological sciences and intelligent productivity platforms.

For more information, visit Haier Biomedical.